The androgen receptor in prostate cancer: Therapy target in search of an integrated diagnostic test

Advances in Anatomic Pathology

Volumn 14, Issue 5, 2007, Pages 353-357

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Androgen ablation; AR; AR coregulators; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTENEDIONE; BETA CATENIN; BICALUTAMIDE; CHAPERONE; CYTOKINE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; GROWTH HORMONE; HEAT SHOCK PROTEIN; INTERLEUKIN 6; RECEPTOR BLOCKING AGENT; RNA POLYMERASE;

AGONIST; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CARCINOGENESIS; CHROMATIN STRUCTURE; DIAGNOSTIC TEST; DNA STRUCTURE; DRUG TARGETING; HUMAN; METASTASIS; NEEDLE BIOPSY; PHARMACOLOGICAL BLOCKING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC TESTS, ROUTINE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANS-ACTIVATORS;

EID: 34548171468     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31814a52c4     Document Type: Review

References (17)

1. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227-238.
2. Raclaw KA, Tindall DJ. The androgen receptor and hormonal based therapies. In: Ross JS, Foster CS, eds. The Molecular Oncology of Prostate Cancer. Boston: Jones and Bartlett Publishers; 2007:210-230.
3. Chmelar R, Buchanan G, Need EF, et al. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 2007;120:719-733.
4. Eder IE, Haag P, Bartsch G, et al. Targeting the androgen receptor in hormone-refractory prostate cancer - new concepts. Future Oncol. 2005;1:93-101.
5. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
6. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci. 1992;89:6319-6323.
7. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer. 1993;71:2574-2580.
8. Strom SS, Gu Y, Zhang H, et al. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004;60:343-351.
9. Li R, Wheeler T, Dai H, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004;28:928-934.
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39.
11. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate. 1992;20:281-295.
12. Buchanan G, Greenberg NM, Sher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001;7:1273-1281.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
14. Schnitt SJ. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? J Clin Oncol. 2006;24:1797-1799.
15. Ross JS. Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need. Future Oncol. 2005;1:439-441.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing n breast cancer. J Clin Oncol. 2007;25:118-145.
17. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:995-1000.